skip to content

It's a New Day in Public Health.

The Florida Department of Health works to protect, promote & improve the health of all people in Florida through integrated state, county, & community efforts.

skip to content

E-FORCSE Home Page

E-FORCSE, Florida Prescription Drug Monitoring Program

Important Legislative Update

Senate Bill 964 passed during the 2016 Legislative Session authorizing a designee direct access to request and receive information from the database on behalf of a pharmacy, prescriber or dispenser. This provision will become effective July 1, 2016. 

To view the full text, click here.

The Department published a Notice of Rulemaking on May 18, 2016, to amend rule 64K-1.003, Florida Administrative Code, to implement the changes made in Senate Bill 964.  To view the Notice of Rule Rulemaking, click here.

The anticipated implementation date of designee access is January 1, 2017*, or upon adoption of the amended rule.

*Implementation date subject to change

Additional information regarding designee registration and access requirements will be disseminated in the coming weeks.

Welcome to E-FORCSE®, Florida's Prescription Drug Monitoring Program

The Florida Prescription Drug Monitoring Program, known as E-FORCSE® (Electronic-Florida Online Reporting of Controlled Substance Evaluation Program), was created by the 2009 Florida Legislature in an initiative to encourage safer prescribing of controlled substances and to reduce drug abuse and diversion within the state of Florida.

E-FORCSE® has selected Health Information Designs, LLC, to develop a database that collects and stores prescribing and dispensing data for controlled substances in Schedules II, III, and IV.  The purpose of the PDMP is to provide the information that is collected in the database to health care practitioners to guide their decisions in prescribing and dispensing these highly abused prescription drugs.

Section 893.055, Florida Statutes, requires health care practitioners to report to the PDMP each time a controlled substance is dispensed to an individual.  The information is reported through the electronic system as soon as possible but not more than 7 days after dispensing.  This reporting timeframe ensures that health care practitioners have the most up-to-date information available.

E-FORCSE® complies with the Health Insurance Portability and Accountability Act (HIPAA) as it pertains to protected health information (PHI), electronic protected health information (EPHI), and all other relevant state and federal privacy and security laws and regulations.  The information collected in the system will be used by the PDMP to encourage safer prescribing of controlled substances and to reduce drug abuse and diversion within the state of Florida.

Pharmacy & Dispensing Practitioner Controlled Substance Reporting Requirements:

The Department of Health’s Prescription Drug Monitoring Program called E-FORCSE collects, maintains, and stores controlled substance prescription dispensing information in its database and makes the information available to health care practitioners and law enforcement and regulatory agencies during active investigations.  Section 893.055, F.S., requires all practitioners who dispense controlled substances listed in schedules II, III, or IV, as defined in section 893.03, F.S., to report to E-FORCSE within 7 days each time a controlled substance is dispensed to an individual, unless it is one of the acts of dispensing or administering which are exempt from reporting under subsection 893.055(5), F.S. For more information visit,

Wholesale Distributor, Manufacturer or Repackager Controlled Substance Reporting Requirements:

The Department of Business and Professional Regulation, Division of Drugs, Devices and Cosmetics Program, Controlled Substance Registry collects and stores controlled substance receipts and distributions in its registry. Section 499.0121(14), Florida Statutes (F.S.) requires each prescription drug wholesale distributor, whether in state or out-of-state, retail pharmacy drug wholesale distributor, manufacturer, or repackager that engages in the wholesale distribution of controlled substances to report receipts and distributions of controlled substances listed in Schedule II through V, as provided in s. 893.03, F.S., monthly by the 20th of the next month.  For more information visit

This project was supported by Grant No. 2009-PM-BX-4004 awarded by the Bureau of Justice Assistance, Office of Justice Program, U.S. Department of Justice.